MOTS-c Peptide Benefits: Insulin & Endurance (2026)

Research findings on exercise performance:

Systemic MOTS-c administration significantly enhanced physical performance in young (2-month), middle-aged (12-month), and old (22-month) mice, with the most pronounced effects in older animals (Reynolds et al., 2021)

Exercise increases endogenous MOTS-c levels in skeletal muscle, and MOTS-c regulates skeletal muscle stress responses during physical activity (Reynolds et al., 2021)

MOTS-c boosts skeletal muscle stress responses and enhances metabolic adaptation to exercise, including stimulating thermogenesis in subcutaneous white adipose tissue (Kim et al., 2022)

MOTS-c expression in skeletal muscle of healthy aging men is associated with myofiber composition, suggesting a role in maintaining muscle quality during aging (D'Souza et al., 2020)

These findings position MOTS-c as an exercise mimetic that may partially replicate the metabolic benefits of physical activity, though it is not a replacement for exercise itself.

Metabolic Health and Insulin Sensitivity

The metabolic effects of MOTS-c were among the first identified and remain the most extensively studied. MOTS-c targets skeletal muscle, the largest insulin-sensitive tissue in the body, to regulate glucose metabolism.

Key metabolic findings:

MOTS-c treatment in mice prevented both age-dependent and high-fat diet-induced insulin resistance. The primary mechanism involves inhibition of the de novo purine biosynthesis pathway, leading to AMPK activation in skeletal muscle (Lee et al., 2015)

Acute MOTS-c treatment (5 mg/kg) in mice on a high-fat diet prevented hyperinsulinemia and improved glucose tolerance (Lee et al., 2015)

Plasma MOTS-c levels correlate with HOMA-IR (a measure of insulin resistance) in human males, suggesting endogenous MOTS-c plays a role in metabolic regulation (D'Souza et al., 2020)

MOTS-c gene polymorphisms have been associated with metabolic traits and potentially with human lifespan in population studies (Fuku et al., 2015)

These insulin-sensitizing effects are primarily mediated through the AMPK pathway, the same metabolic sensor activated by exercise and caloric restriction.

Fat Metabolism

MOTS-c influences fat metabolism through multiple mechanisms, including direct effects on adipose tissue and indirect effects through skeletal muscle glucose utilization.

Research on fat metabolism:

MOTS-c treatment prevented diet-induced obesity in mice fed a high-fat diet, reducing weight gain and liver fat accumulation (Lee et al., 2015)

Exogenous MOTS-c stimulates thermogenesis in subcutaneous white adipose tissue, enhancing energy expenditure through increased heat production (Kim et al., 2022)

MOTS-c regulates both muscle and fat metabolism as an integrated metabolic signal, shifting the body toward greater glucose utilization and reduced fat storage (Lu et al., 2016)

The fat metabolic effects of MOTS-c are secondary to its primary mechanism of AMPK activation and metabolic reprogramming rather than direct lipolysis.

Aging and Longevity

MOTS-c levels change with age, and supplementation in aged animals produces measurable improvements in physical function and metabolic health.

Aging-related findings:

Endogenous MOTS-c levels decline in plasma with aging, while skeletal muscle expression increases, potentially as a compensatory mechanism (D'Souza et al., 2020)

Late-life initiated intermittent MOTS-c treatment (15 mg/kg, 3x/week) in 23.5-month-old mice improved physical capacity and trended toward increased lifespan (Reynolds et al., 2021)

MOTS-c gene polymorphisms (m.1382A>C) have been associated with exceptional longevity in Japanese populations, suggesting a genetic link between MOTS-c signaling and human lifespan (Fuku et al., reported in Zarse & Ristow, 2015)

Age-dependent metabolic decline is associated with reduced mitochondrial function, and MOTS-c supplementation partially reverses age-related metabolic dysfunction in mice (Reynolds et al., 2021)

These findings suggest MOTS-c may be relevant to healthy aging, but human longevity trials have not been conducted.

Inflammation

MOTS-c exerts anti-inflammatory effects primarily through AMPK activation, which inhibits pro-inflammatory signaling pathways.

Anti-inflammatory research:

Intraperitoneal MOTS-c administration produced antinociceptive and anti-inflammatory effects in the mouse formalin test through activation of the AMPK pathway and inhibition of MAP kinase-c-fos signaling (Ming et al., 2020)

An oral MOTS-c analogue ameliorated dextran sulfate sodium-induced colitis in mice by inhibiting inflammation and apoptosis through AMPK activation (Kang et al., 2023)

AMPK activation by MOTS-c inhibits NF-kB signaling, a central mediator of inflammatory responses, reducing the production of pro-inflammatory cytokines (Lu et al., 2022)

The anti-inflammatory effects of MOTS-c are mechanistically linked to its metabolic actions, as AMPK activation simultaneously regulates both energy metabolism and inflammatory signaling.

What MOTS-c Does NOT Do

Based on current evidence, MOTS-c:

Does not directly build muscle. It enhances exercise performance and metabolic adaptation, but it is not anabolic in the way growth hormone secretagogues are.

Has not been tested in human clinical trials for most of its reported benefits. The majority of evidence comes from mouse models and cell culture studies.

Does not replace exercise. While it mimics some metabolic effects of physical activity, it does not replicate the full spectrum of exercise benefits.

Is not FDA-approved for any medical condition. It remains a research compound.